Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?
Nearly 90% Discount To Astellas/Pfizer’s Xtandi
Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.
